Mobile

A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride (...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004286-15

A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the sustained effectiveness (for a minimum of 28 days) of intravenous (IV) forodesine hydrochloride infusions in patients with advanced T-cell leukemia (precursor T-lymphoblastic leukemia/lymphoma or T-cell prolymphocytic leukemia [T-PLL])

Critère d'inclusion

  • Advanced T-cell Leukaemia (either T-cell Acute Lymphoblastic Leukaemia [T-ALL] or T-cell Prolymphocytic Leukaemia [T-PLL]) or Aleukaemic Leukaemia

Liens